Document Heading:
Amrutanjan Health Care Limited – Investor Presentation Summary
Key Operational Highlights
- Sales infrastructure (stockist network) increased by 7% in Q1 FY27 compared to previous period.
- Distribution sales productive calls increased by 9% in Q1 FY27.
- Total lines sold increased by 20% in Q1 FY27.
- Total outlets coverage increased by 17% in Q1 FY27.
- Effective outlet coverage increased by 8% in Q1 FY27.
- New launches (razors and plaster) contributed 4% to total AHCL sales in Q1 FY27.
- Razors generated revenue of Rs. 3 crore in Q1 FY27 and reached distribution presence of 70,000 outlets.
- Plastry line of wound care products generated revenue of Rs. 1.12 crore in Q1 FY27.
Key drivers of operational performance: Execution enhancement initiatives implemented to improve operational effectiveness.
Segment-wise Performance
- Pain Management category contributed 65% of company revenue; per IQVIA data, volume growth was -3.4% year-over-year in Q1 FY27, compared to 6.6% growth in Q1 FY26.
- Women's Hygiene category grew robustly with demand across town classes, led by larger pads under the Comfy brand.
- Personal Care portfolio: Comfy Close and Clean women's razor and Amrutanjan Smoothe men's razor generated revenue of Rs. 3 crore in Q1 FY27.
- Beverage business: Electro+ WHO ORS and Enerlyte brands posted 11% growth in Q1 FY27, though category remains soft due to FSSAI regulations.
Explanation of significant changes: Pain management decline attributed to GST implementation impacting retailer demand and high base effect; women's hygiene growth driven by strong demand.
Financial Highlights
- Advertisement spend for Q1 FY27 was Rs. 3.03 crore against Rs. 1.59 crore for Q1 FY26.
- Advertisement spend for Comfy brand was Rs. 2.14 crore for Q1 FY27 against Rs. 0.48 crore for Q1 FY26.
- Exceptional item of Rs. 2.03 crore recorded due to lease rent settlement with Government of Tamil Nadu.
- Majority of raw material and packing material prices were higher than Q1 FY26, except menthol crystal price which was lower.
Drivers of financial performance: Not specified in detail.
Comparison to market estimates: Not specified.
Key Risks: Raw material price hikes due to war in West Asia, regulatory risks from FSSAI changes.
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not specified.
Balance Sheet Snapshot
Not specified.
Capex & Cash Flow Health
- Capital Expenditure: ₹150 crore investment in new sanitary napkin manufacturing facility in Telangana, commissioned recently.
- Free Cash Flow: Not specified.
- Operating Cash Flow: Not specified.
- Net Debt Movement: Not specified.
Investment Rationale: Strengthening manufacturing capabilities for feminine hygiene products under "Make in India" initiative.
Strategic & R&D Initiatives
- Investments in Innovation: New product launches including women's razors, men's razors, antiseptic plaster, ortho pain oil, and nasal spray in Q4 FY26.
- Expected impact on growth: Razors projected annual revenue of Rs. 15 crore for FY27; plastry targeted at Rs. 10 crore for the year.
- Strategic Rationale: Entering new categories to complement existing portfolio and expand into high-growth markets.
Industry Trends & Business Environment
- Macro/Industry Trends: GST implementation caused retailer demand erosion in pain management category; FSSAI regulations restricted marketing of electrolyte drinks; war in West Asia affecting COGS through inflationary pressures.
- Impact on Company: Pain management volume decline impacted overall performance; beverage category growth softened; cost increases covered partially by price hikes.
Management Commentary & Growth Outlook
- Strategic Outlook: Focus on monetizing new Comfy plant and ensuring brand profitability for the year; confidence in double-digit revenue and operating profit growth for FY27.
- FY Guidance: Projected revenue growth of double digits; operating profit growth of double digits.
- Market Share Targets: Not specified.
- Risks and Opportunities: Reduction in one-time charges (lease rent matter closed, wage code, inventory loss) expected in FY27; offset of reduced interest income by lower one-time charges.